OneSource Specialty Pharma Limited has announced that its partner, Dr. Reddy’s Laboratories Ltd., has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, a version of Ozempic®. OneSource serves as the strategic manufacturing partner, providing essential scale-up and commercial production services. The product will be manufactured at OneSource’s US-FDA approved flagship facility in Bengaluru, highlighting the company’s strong capabilities in supporting complex peptide-based pharmaceutical developments.
Strategic Manufacturing Milestone
On April 29, 2026, OneSource Specialty Pharma Limited confirmed a major regulatory milestone for its collaborative program with Dr. Reddy’s Laboratories. The receipt of a Notice of Compliance from Health Canada for a generic Semaglutide Injection marks a significant advancement in the commercialization of this complex therapy.
Partnership Impact and Manufacturing Excellence
OneSource acts as the key manufacturing partner for this program. By leveraging its US-FDA approved flagship facility located in Bengaluru, the company ensures a reliable and scalable supply chain for global markets. Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma, emphasized that this approval validates the firm’s expertise in peptide development and its ability to provide high-end contract development and manufacturing organization (CDMO) services for intricate pharmaceutical products.
About OneSource Capabilities
As a pure-play specialty pharmaceutical CDMO, OneSource focuses on complex areas including biologics, drug-device combinations, and sterile injectables. With a dedicated team of over 1,600 professionals and five state-of-the-art facilities, the company continues to provide end-to-end solutions for global pharmaceutical entities, maintaining a robust compliance track record in the highly regulated life sciences sector.
Source: BSE
